Loading
A phase 3 trial testing HS-20093 in osteosarcoma, active and no longer recruiting.
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure is a phase 3 interventional study registered as NCT06935409, led by Hansoh BioMedical R&D, and active but no longer recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of HS-20093 for Injection Versus Gemcitabine in Combination With Docetaxel in the Treatment of Osteosarcoma After Previous Second-line Treatment Failure (ARTEMIS-011). Planned enrolment is 117 participants (estimated). The study started in 2025-04-25 and primary completion is expected in 2026-08-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HS-20093, Hansoh Pharmaceutical, Osteosarcoma.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/